Lumakras CODEBREAK 100 study shows two year overall survival of 32.5% in KRAS G12C mutated NSCLC.
Amgen has announced the presentation of long-term efficacy and safety data from the CodeBreaK 100 Phase 1/II trial in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who received Lumakras (sotorasib).
The two-year follow-up data was presented orally as part of a clinical trials plenary session at the American Association for Cancer Research (AACR) annual meeting on April 10, 2022.
Lumakras is the first and only KRASG12C inhibitor to-date to show long-term clinical benefit and overall survival in patients with NSCLC harboring the KRAS G12C mutation.
In this long-term, two-year analysis of 174 heavily pre-treated patients (172 with baseline measurable lesion(s)), Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, disease control rate (DCR) of 83.7% and median duration of response (DOR) of 12.3 months. Five patients achieved complete responses and 65 patients achieved partial responses. The results also showed median progression-free survival (PFS) of 6.3 months and overall survival (OS) of 12.5 months with 32.5% of patients still alive at two years. No new safety signals for Lumakras were identified with the long-term follow-up.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.